immuno drugs

Question 1

cyclosporine A
tacrolimus

moa and s/e that effect both

Answer 1

calcineurin inhibitor
blocks cytokine transciption, therefore prevenet lymphocyte proliferation and effector function

blocks expression of IL 2

nephrotoxic
htn
neurotoxic

Question 2

calcinurein inhib that has diabetogenic

Answer 2

tacrolimus

Question 3

calcinuerein inhib that has more dysmorphia and examples

Answer 3

cyclosporin

hirsuitism
gingival hypertrophy (like phenytoin as well)

Question 4

ipilimumab

Answer 4

alpha CTLA4 Ab

use for advanced melanoma

Question 5

alpha CTLA4 ab

Answer 5

ipilimumab

Question 6

alpha PD-1 A

Answer 6

pembrolizumab

nivolumab

Question 7

pembrolizumab

Answer 7

alpha PD-1 ab

Question 8

nivolumab

Answer 8

alpha PD-1 ab

Question 9

cyclophosphamide

use and Moa

Answer 9

alkylates guanine base of DNA
effects B>T
use in many vasculitides?
wegener's SLE
anti cancer

Question 10

effect B>T
infertility
haemorrhagic cystitis
malig
PCP

Answer 10

cyclophosphamide

Question 11

cyclophosphamide

side effects

Answer 11

infertility (m»F)
hamorrhagic cyctitis
malignancy (bladder, haem, non melanoma skin)
PCP

Question 12

corticosteroids

use and moa

Answer 12

inhibits phosphlipase A1 - reduce prostaglandin

decrease phagocytosis, release of proteolytic enzymes, traffic of phagoctye to inflamme tissue

lymphopenia, block cytopkine gene expression, dec ab prduction, promote apoptosis

Question 13

azathioprine

Answer 13

blocks de novov purine synthesis
pref inhibit T
auto immune
auto inflamm - ibd

Question 14

azathioprine s/e

Answer 14

tmpt

hepatotoxict

Question 15

mycophenolate mofetil

use and moa

Answer 15

blocks de novo nucletoide synthesis
T>B
transplantation
auto immune
vasculitiis (alter to cyclophospamide)

Question 16

mycophenolate mofetil

side effects

Answer 16

PML from JC virus

herpes reactivation

Question 17

plasmapheresis - indication

Answer 17

Goodpastures
myasthenia gravis
severe vascular regjection

Question 18

BMT indications

Answer 18

SCID
leukcotye adhesion defect
malignancy

Question 19

Human normal IG replacement therapy - indications

Answer 19

Primary ab def
X linked agammaglob (Brutons, BTK gene)
X linked hyper IgM syndrome (CD40L on T)
CVID (epitaxis, lung, GI prob, MHC III? i think, normal IgM with low others)

Secondary
Haem malignancies like
CLL
MM
post BMT

passive immunisations
CMV
VZIG
rabies
HBV IG
tetanus

Question 20

recombinant cytokines
indications for
1. IFN alpha
2. beta
3. gamma

Answer 20

alpha
HCV, HBV, HHV8, hairy cell, CML, MM

beta
RRMS

gamma
CGD

Question 21

JAK inhibitora

Answer 21

tofacitinib

Question 22

tofacitnib

Answer 22

JAK inhibitor

Question 23

PDE4 inhibitor

Answer 23

apremilast

but also effects PKA pathway

Question 24

apreimilast

Answer 24

PDE4 inhibitor

but also effects PKA pathway

Question 25

Anti-thymocyte globulin (take IV)

Answer 25

allograft regjection (renal, heart)
from rabbit
ab are anything t cell

Question 26

basiliximab

daclizumab

Answer 26

ab specific for CD25
anti IL2 R

prophylaxis of allograft rejection
IV before and after transplant surgery (espesh kidney transplants)

stop t cell prolif

Question 27

anti IL2 R

Answer 27

basilximab
daclizumab
ab specific for CD25

Question 28

abatacept

Answer 28

CTLA4-Ig fusion protein

RA

reduces T cell activation

Question 29

CTLA4-Ig fusion protein

RA

Answer 29

Abatacept

Question 30

which cell suface molecules you DON’T use and why

Answer 30

TGN1412 (anti CD 28)
cytokine storm

efalizumab (anti LFA1)
fatal cases of PML (prog multifocal leukoenceph)

Question 31

Rituximab

Answer 31

CD20 specific

lymphoma
RA
SLE

depletes mature B cells - leaves plasma cells

consider Hep B core Ab+ if using this

Question 32

anti CD20 and indications

Answer 32

RItuximab
lymphoma
RA
sle

Question 33

Natalizumab

Answer 33

alpha4 integrin

RRMS
(Crohn’s)

inhibits T cell migration

Question 34

Tocilizumab

Answer 34

ab at IL6 receptor

castleman’s disease
RA

red macro, t,b and neutrophil activation

Question 35

alpha4 integrin ab

Answer 35

natalizumab

rrms
crohns

Question 36

IL6 R ab

Answer 36

tocilzumab

castleman’s
RA

Question 37

anti TNF alpha

Answer 37

infliximab
adalimumab
certolizumab
golimumab

RA
ank spond
psoriasis and p. arthritis
IBD

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 38

infliximab

Answer 38

anti TNF alpha

RA
ank spond
Psoriasis and p. arthritis
IBD

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 39

adalimumab

Answer 39

anti TNF alpha

RA
ank spond
Psoriasis and p. arthritis
IBD

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 40

certolizumab

Answer 40

anti TNF alpha

RA
ank spond
Psoriasis and p. arthritis
IBD

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 41

golimumab

Answer 41

anti TNF alpha

RA
ank spond
Psoriasis and p. arthritis
IBD

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 42

TNF alpha antagonist (fusion protein)

Answer 42

Etanercept

RA
ank spond
psoriasis and p. arthritis

NO IBD USAGE

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 43

etanercept

Answer 43

TNF alpha antag
fusion protein

RA
ank spond
psoriasis and p. arthritis

NO IBD USAGE

toxicity - infection (TB, HBV, HCV), lupus-like conditions

Question 44

ustekinumab

Answer 44

ab to p40 subuint of
IL12 (p40+p35)
IL23 (p40+p19)

psoriasis and p arthritis

toxicity - infection TB

Question 45

ab to p40 subuint of
IL12 (p40+p35)
IL23 (p40+p19)

Answer 45

USTEKINUMAB

Question 46

denosumab

Answer 46

ab at RANK ligand

osteoporosis

toxictiy - avascular nerosis of jaw

Question 47

inihibit RANK ligand

Answer 47

denosumab

osteoporosis

Question 48

osteoporosis

Answer 48

denosumab - RANKL